| Bioactivity | (R)-Azasetron besylate (SENS-401) is an orally active calcineurin inhibitor. (R)-Azasetron besylate reduces Cisplatin (HY-17394)-induced hearing loss and cochlear damage[1][2]. |
| Name | (R)-Azasetron besylate |
| CAS | 2025360-91-0 |
| Formula | C23H26ClN3O6S |
| Molar Mass | 507.99 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Petremann M, et al. SENS-401 Effectively Reduces Severe Acoustic Trauma-Induced Hearing Loss in Male Rats With Twice Daily Administration Delayed up to 96 hours. Otol Neurotol. 2019 Feb;40(2):254-263. [2]. Petremann M, et al. Oral Administration of Clinical Stage Drug Candidate SENS-401 Effectively Reduces Cisplatin-induced Hearing Loss in Rats. Otol Neurotol. 2017 Oct;38(9):1355-1361. |
(R)-Azasetron besylate
CAS: 2025360-91-0 F: C23H26ClN3O6S W: 507.99
(R)-Azasetron besylate (SENS-401) is an orally active calcineurin inhibitor. (R)-Azasetron besylate reduces Cisplatin (H
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.